Extra gene coding capacity of SARS-CoV-2 provides a virus engineering platform for in vitro and in vivo applications
The genomic flexibility of orthocoronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is showcased by the presence of accessory genes, which vary in number among virus species and strains. Given this flexibility, the viral coding capacity can be artificially expanded to express a heterologous gene from the viral genome, thereby enabling the development of a viral vector platform. Here, we systematically explored the extra gene coding capacity of SARS-CoV-2 by inserting an extra reporter gene at every intergenic region in its genome. We revealed the entire scheme of its extra gene expression and identified a genomic location that stably expresses reporter genes while maintaining the wild-type viral phenotype. Using this construct, we developed a set of fluorescent and luminescent reporter SARS-CoV-2 viruses available for in vivo flow cytometry and in vitro antiviral screening. Flow cytometric analysis with these reporter viruses revealed cell type-specific dynamics of SARS-CoV-2 infection in the lung tissue of K18-hACE2 mice. Our findings offer a platform for SARS-CoV-2 genome engineering, providing a set of reporter viruses for research applications.
Authors
- Taksoo Kim
- Sangam Kandel (ORCID: https://orcid.org/0000-0002-2875-6462)
- Makoto Kuroda (ORCID: https://orcid.org/0000-0002-0487-4405)
- Asim Biswas (ORCID: https://orcid.org/0000-0002-4999-4697)
- Peter Halfmann (ORCID: https://orcid.org/0000-0002-1648-1625)
- Yoshihiro Kawaoka (ORCID: https://orcid.org/0000-0001-5061-8296)
Institutions
- University of Wisconsin–Madison (US)
- National Center for Global Health and Medicine (JP)
- Office of Readiness and Response (US)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-06-24
- DOI
- https://doi.org/10.1073/pnas.2532920123
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- National Institutes of Health